A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

March 4, 2025

Study Completion Date

February 27, 2026

Conditions

Non Small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

HLX208+HLX10

HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY